Citigroup Inc Oncocyte Corp Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.2 - $0.49 $181 - $445	-909 Reduced 86.9%	137 $0
Q4 2022 Feb 09, 2023	BUY	$0.25 - $15.6 $43 - $2,714	174 Added 19.95%	1,046 $0
Q3 2022 Nov 10, 2022	SELL	$0.76 - $15.98 $2,012 - $42,315	-2,648 Reduced 75.23%	872 $1,000
Q2 2022 Aug 10, 2022	SELL	$0.86 - $1.53 $659 - $1,173	-767 Reduced 17.89%	3,520 $3,000
Q1 2022 May 12, 2022	SELL	$1.15 - $2.25 $16,090 - $31,482	-13,992 Reduced 76.55%	4,287 $6,000
Q4 2021 Feb 10, 2022	BUY	$2.04 - $3.59 $23,307 - $41,015	11,425 Added 166.69%	18,279 $39,000
Q3 2021 Nov 10, 2021	BUY	$3.53 - $5.89 $24,194 - $40,370	6,854 New	6,854 $24,000

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $266M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.